Associations Between Antiretroviral Regimen and Changes in Blood Pressure: Results From the D2EFT Study

Clin Infect Dis. 2025 Feb 5;80(1):160-163. doi: 10.1093/cid/ciae256.

Abstract

In this randomized controlled study, individuals taking dolutegravir+darunavir/ritonavir had greater increases in systolic and diastolic blood pressure than those taking 2 nucleoside reverse-transcriptase inhibitors+darunavir/ritonavir at week-48. The difference remained significant after controlling for confounding factors, including weight gain.

Trial registration: ClinicalTrials.gov NCT03017872.

Keywords: HIV; cardiovascular risk; dolutegravir; hypertension; low- and middle-income countries.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Anti-HIV Agents* / adverse effects
  • Anti-HIV Agents* / therapeutic use
  • Anti-Retroviral Agents* / adverse effects
  • Anti-Retroviral Agents* / therapeutic use
  • Antiretroviral Therapy, Highly Active* / adverse effects
  • Blood Pressure* / drug effects
  • Clinical Trials, Phase IV as Topic
  • Female
  • HIV Infections* / drug therapy
  • Heterocyclic Compounds, 3-Ring / adverse effects
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Oxazines
  • Piperazines
  • Pyridones
  • Randomized Controlled Trials as Topic
  • Ritonavir / adverse effects
  • Ritonavir / therapeutic use

Substances

  • Anti-HIV Agents
  • Anti-Retroviral Agents
  • dolutegravir
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • Ritonavir

Associated data

  • ClinicalTrials.gov/NCT03017872